-
公开(公告)号：US20180161314A1
公开(公告)日：2018-06-14
申请号：US15891727
申请日：2018-02-08
发明人： Barry D. Quart
IPC分类号： A61K31/4196 , A61K31/426 , A61K31/519
CPC分类号： A61K31/4196 , A61K31/426 , A61K31/519 , A61K2300/00 , A61P13/12 , A61P19/02
摘要： Provided herein are methods of treating gout, treating hyperuricemia, lowering serum uric acid, or the like with compounds of formula (I) have the following structure Further, provided herein are compositions comprising a compound of formula (I).
-
公开(公告)号：US20160221969A1
公开(公告)日：2016-08-04
申请号：US14757583
申请日：2015-12-23
IPC分类号： C07D249/12 , C07D401/04 , C07H19/06 , C07H19/10 , C07D249/14 , C07H19/16
CPC分类号： C07D249/12 , C07D249/14 , C07D401/04 , C07D405/12 , C07H19/06 , C07H19/10 , C07H19/16
摘要： Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
-
3.发明申请公开(公告)号：US20160214947A1
公开(公告)日：2016-07-28
申请号：US15048110
申请日：2016-02-19
发明人： Esmir GUNIC , Gabriel GALVIN
IPC分类号： C07D249/12
CPC分类号： C07D249/12
摘要： Described herein are certain processes for the synthesis of compounds of Formula (I):
-
4.发明授权Preparation of (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 有权（R）-N-（3,4-二氟-2-（2-氟-4-碘苯基氨基）-6-甲氧基苯基）-1-（2,3-二羟基丙基）环丙烷-1-磺酰胺和（S） -N-（3,4-二氟-2-（2-氟-4-碘苯基氨基）-6-甲氧基苯基）-1-（2,3-二羟丙基）环丙烷-1-磺酰胺公开(公告)号：US09296686B2
公开(公告)日：2016-03-29
申请号：US14467424
申请日：2014-08-25
IPC分类号： C07C303/00 , C07C303/38 , C07C317/18 , C07D317/26
CPC分类号： C07C303/38 , C07C317/18 , C07C2601/02 , C07D317/18 , C07D317/26 , C07C311/28
摘要： The present invention relates to the preparation of (R)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.
摘要翻译： 本发明涉及制备（R）-N-（3,4-二氟-2-（2-氟-4-碘苯基氨基）-6-甲氧基苯基）-1-（2,3-二羟基丙基）环丙烷-1 - 磺酰胺和（S）-N-（3,4-二氟-2-（2-氟-4-碘苯基氨基）-6-甲氧基苯基）-1-（2,3-二羟丙基）环丙烷-1-磺酰胺。
-
5.发明申请POLYMORPHIC, CRYSTALLINE AND MESOPHASE FORMS OF SODIUM 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO) ACETATE, AND USES THEREOF 审中-公开2-（5-溴-4-（4-环丙基苯基）-1-基）-4H-1,2,4-三唑-3-基）乙酸钠的多晶，晶体和麦芽酚形式及其用途公开(公告)号：US20130345271A1
公开(公告)日：2013-12-26
申请号：US13954736
申请日：2013-07-30
IPC分类号： C07D249/12
CPC分类号： C07D249/12
摘要： Crystalline polymorphs and solid mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate are described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are provided.
摘要翻译： 描述了2-（5-溴-4-（4-环丙基萘-1-基）-4H-1,2,4-三唑-3-基硫基）乙酸钠的结晶多晶型物和固体中间相形式。 此外，还提供了用于治疗各种疾病和病症的这些组合物的药物组合物和用途。
-
公开(公告)号：US08541589B2
公开(公告)日：2013-09-24
申请号：US13857108
申请日：2013-04-04
发明人： Samedy Ouk , Esmir Gunic , Jean-Michel Vernier
IPC分类号： A61K31/519 , C07D211/72
CPC分类号： C07D213/70 , A61K31/426 , A61K31/4418 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/4725 , A61K31/4965 , A61K31/497 , A61K31/502 , A61K31/505 , A61K31/506 , A61K31/519 , A61K45/06 , C07D239/38 , C07D241/18 , C07D401/04 , C07D401/10 , C07D403/04 , C07D403/10 , C07D405/04 , C07D405/10 , C07D417/04 , C07D417/10
摘要： Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
摘要翻译： 本文描述了可用于调节血液尿酸水平的化合物，含有它们的制剂和使用它们的方法。 在一些实施方案中，本文所述的化合物用于治疗或预防与尿酸异常水平相关的病症。
-
公开(公告)号：US20230011269A1
公开(公告)日：2023-01-12
申请号：US17808390
申请日：2022-06-23
发明人： Joanne REILAND WAKEMAN , Colin ROWLINGS , Sha LIU , Gerry BURKE , Christian VON CORSWANT , Christer TANNERGREN , Johan HJÄRTSTAM
IPC分类号： A61K9/20 , A61K9/14 , A61K9/00 , A61K9/48 , A61K9/50 , A61K31/426 , A61K31/4418 , A61K45/06
摘要： The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonaphthalen-1-yl)pyridine-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
-
公开(公告)号：US20210171466A1
公开(公告)日：2021-06-10
申请号：US17123380
申请日：2020-12-16
发明人： Samedy OUK , Esmir GUNIC , Jean-Michel VERNIER , Chixu CHEN
IPC分类号： C07D213/70 , C07D239/38 , C07D241/18 , C07D401/04 , C07D403/04 , C07D405/04 , C07D417/04 , A61K31/426 , A61K31/4418 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/4725 , A61K31/4965 , A61K31/497 , A61K31/502 , A61K31/505 , A61K31/506 , A61K31/519 , A61K45/06 , C07D401/10 , C07D403/10 , C07D405/10 , C07D417/10
摘要： Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
-
公开(公告)号：US20190142805A1
公开(公告)日：2019-05-16
申请号：US16246833
申请日：2019-01-14
发明人： Barry D. Quart , Jean-Luc Giradet , Esmir Gunic , Li-Tain Yeh
IPC分类号： A61K31/4196 , C07H7/02 , A61K31/7056 , C07H19/16 , A61K31/7068 , C07D249/12 , A61K31/7076 , A61K45/06 , C07D249/14 , C07H19/06 , A61K31/7072
摘要： Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
-
公开(公告)号：US20190015392A1
公开(公告)日：2019-01-17
申请号：US16135153
申请日：2018-09-19
发明人： Jeffrey Miner , Barry D. Quart , Jean-Luc Girardet
IPC分类号： A61K31/426 , A61K45/06 , A61K31/519 , A61K31/4196
摘要： Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are described.
-
-
-
-
-
-
-
-
-
搜索结果
54 条记录 (耗时 0.028 秒)
